The short answer
Calcium can reduce bictegravir absorption when taken together fasting. Biktarvy and calcium supplements or antacids can be taken together with food under the current U.S. instructions. If you take them without food, ask your HIV pharmacist for the correct schedule rather than using a two-hour gap in either direction.
What this answer covers
Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured.
- Supplement or preparation
- Calcium
- Medication ingredient
- bictegravir
What did the calcium study show?
Healthy adults received Biktarvy with calcium carbonate, a common supplement and antacid ingredient. Taking them together fasting reduced bictegravir exposure by about one third. With a meal, exposure was similar to the reference dose of Biktarvy taken alone fasting. The study measured drug concentrations after single doses; it did not measure treatment failure in people taking calcium every day.
Can I take calcium with my Biktarvy dose?
The current U.S. label allows Biktarvy and calcium supplements or antacids to be taken together with food. It discourages routine simultaneous fasting use and taking Biktarvy two hours after calcium. NIH guidance also distinguishes taking bictegravir before a mineral product from taking it afterward. A pharmacist can match the schedule to your meal pattern and any other ingredients in the supplement.
Do pregnancy or mixed mineral products change the advice?
The label gives specific pregnancy instructions: calcium and Biktarvy may be taken together with food, while fasting use requires Biktarvy at least two hours before or six hours after the calcium product. A prenatal supplement may contain iron or other minerals as well. An aluminum/magnesium antacid has a different rule, so the calcium-with-food exception should not be applied to every mixed product.
What details should I bring to a medication review?
Show the complete ingredient list, elemental calcium amount and timing of each daily dose. Calcium carbonate was the preparation directly tested; the exact effect of every salt or high-dose mixture has not been measured. Do not stop Biktarvy or increase its dose yourself. If you have regularly taken calcium and Biktarvy together without food, discuss the schedule and any needed viral-load follow-up with your HIV team.
Evidence and practical considerations
Absorption & effectiveness
Calcium can reduce bictegravir absorption when taken together fasting. Biktarvy and calcium supplements or antacids can be taken together with food under the current U.S. instructions. If you take them without food, ask your HIV pharmacist for the correct schedule rather than using a two-hour gap in either direction.
- Exact scope
- Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured. with Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination
- Medication form and route
- Adult oral bictegravir as Biktarvy 50/200/25 mg fixed combination; oral mineral, supplement or antacid within stated preparation scope
- Timing or duration
- Single-dose fasted and fed comparisons in healthy adults. Long-term treatment outcomes and repeated high-dose calcium use were not measured.
What remains uncertain
- The fed comparison used a fasted-alone reference. Label guidance covers calcium more broadly than the tested carbonate salt; pregnancy has explicit fasting timing instructions. No universal direction-free two-hour interval is established.
Factors that may matter: Exact mineral ingredients, preparation and elemental amount; Biktarvy fixed-combination formulation; Food and direction of administration when applicable; Concurrent mineral products, adherence and viral-load monitoring.
Read the supporting source summaries
Source 1: current U.S. regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People using the fixed combination Biktarvy for HIV treatment; adult-strength tablets contain bictegravir 50 mg, emtricitabine 200 mg and tenofovir alafenamide 25 mg.
Give Biktarvy at least 2 hours before or 6 hours after aluminum/magnesium antacids. Calcium or iron can be taken together with food; routine simultaneous fasting administration or Biktarvy 2 hours after calcium/iron is not recommended. St. John’s wort coadministration is not recommended because bictegravir and tenofovir alafenamide may decrease.
How this applies: Exact bictegravir active ingredient is bridged from bictegravir sodium by the label’s declared equivalent dose. Cation findings concern bictegravir; St. John’s wort can also affect the tenofovir alafenamide component. No emtricitabine interaction is inferred. Exact article scope: Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured.
Combination-product labeling, not evidence for bictegravir monotherapy. Named antacid directions are not direct experiments on every nutritional magnesium/aluminum formulation. The label supplies no echinacea trial or measured interaction for every multivitamin. Pregnancy has explicit additional fasting instructions.
Source 2: U.S. expert clinical treatment guideline
clinicalinfo.hiv.gov · Source check Sep 10, 2026
Population: Adults and adolescents receiving integrase inhibitor regimens for HIV.
Bictegravir mineral directions depend on cation and food. If raltegravir must be used with polyvalent mineral supplements, give it at least 2 hours before or 6 hours after and monitor virologic response. Multivitamin chelation magnitude is uncertain. Raltegravir antacid rules are separate: avoid Al/Mg, and distinguish calcium carbonate 400 mg twice daily from 1,200 mg once daily. Do not coadminister bictegravir with St. John’s wort.
How this applies: Exact-drug management guidance. Bictegravir sodium and raltegravir potassium are interpreted through their labels’ active-moiety equivalents. Calcium/iron food exceptions for bictegravir do not transfer to raltegravir. Exact article scope: Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured.
Expert recommendations include predicted interactions where exact-pair clinical studies are absent. A suggested supplement schedule does not supersede the distinct antacid avoidance instructions. No universal safe dose or virologic risk percentage is established.
Source 3: peer-reviewed prospective human pharmacokinetic study
europepmc.org · Source check Sep 10, 2026
Population: 42 healthy HIV-negative adults aged 18-45 years, in three cohorts of 14; open-label single-dose study conducted in 2016.
Fasted simultaneous bictegravir exposure was lower by 79% with combined Al/Mg antacid, 33% with calcium carbonate and 63% with ferrous fumarate. Bictegravir 2 hours before Al/Mg largely preserved exposure; 2 hours after still reduced it by 52%. With food, calcium exposure ratio was 1.033 and iron ratio 0.838 relative to bictegravir alone fasting; Al/Mg still reduced exposure by 47%.
How this applies: Direct preparation-specific evidence for adult oral bictegravir in Biktarvy. Calcium carbonate and ferrous fumarate findings are explicitly bounded within broader calcium and iron articles. These data do not directly measure every multivitamin, magnesium chelate or aluminum product. Exact article scope: Adult oral Biktarvy and calcium-containing supplements or antacids. Direct pharmacokinetic research used calcium carbonate 1,200 mg, approximately 480 mg elemental calcium. Other calcium salts and multicomponent products were not separately measured.
Single doses in healthy people, not a clinical failure trial. Combined Al/Mg does not isolate either ion. Fed combination arms were compared with a fasted-alone reference, not fed-alone control. Sponsor Gilead participated in design, analysis and writing. Discussion language about regional timing differs from the current U.S. label; the U.S. 2-before/6-after antacid instructions govern the article.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact-drug labeling and guidance checked; original human studies and neutral findings assessed. Current statements adjudicated with formulation, food and directional timing corrections. Article written; clinical sign-off not recorded. | |
| Research summary published |
Article revision: 30343b82c3c26395
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.